The Ministry of Health confirmed 12,092 new cases of dengue in Argentina during epidemiological week 13 (from March 26 to April 1), that is, an increase of 27.7% compared to the previous week. According to the National Epidemiological Bulletin published this Fridaya total of 28,235 cases were registered of which 25,419 acquired the disease in Argentina.
According to the report, the figure exceeds a “26% compared to the same period in 2020 and is 4% below the number of cases for the same period in 2016″. The circulation of the virus has been detected in 14 jurisdictions that correspond to three regions: Central Region (Buenos Aires; Autonomous City of Buenos Aires; Córdoba; Entre Ríos; Santa Fe); NEA region (Corrientes; Formosa; Chaco) and NOA region (Catamarca; Jujuy; La Rioja; Salta; Santiago del Estero and Tucumán).
Also read: Given the increase in dengue cases, Anmat accelerates the analysis of a Japanese vaccine
The provinces with the highest number of detections are Santa Fe Santa Fe (7,429), Tucumán (5,132), Salta (3,820), City of Buenos Aires (3,408), Buenos Aires (2,679) and Santiago del Estero (1,709). The provinces with the highest accumulated incidence (more than 100 reported dengue cases per hundred thousand inhabitants) so far are: Tucumán, Salta, Jujuy, Santa Fe, Santiago del Estero and CABA.
To prevent the transmission of dengue and chikungunya, they recommend avoiding the accumulation of water in containers to which mosquitoes have access (Photo: Analía Garelli/Télam).
Until April 1, registered 14 deaths with positive tests for denguesix women and eight men between the ages of 13 and 87.
Regarding chikungunya fever, “915 cases have been registered so far, of which 348 acquired the infection in the country; 306 are under investigation and 261 acquired the disease abroad. At the moment, the circulation of this virus has been confirmed in 7 jurisdictions: Buenos Aires; CABA; Chaco; Cordova; currents; Formosa and Santa Fe”, it was indicated in the bulletin.
When does the dengue vaccine come out?
as far as he could tell TNthe National Administration of Drugs, Food and Medical Technology (Anmat) is analyzing the Qdenga vaccine, from the Japanese company Takedaand tetravalent serum what It was approved a month ago in Brazil and? could follow the same path in Argentina in the coming days.
Also read: What are the symptoms of dengue and how to prevent it
“The vaccine that is already in Brazil is very interesting because covers four serotypes in one”, highlighted Elena Obieta (MN 76,451), infectious disease specialist at the Hospital de Boulogne (San Isidro) and member of the Argentine Society of Infectious Diseases (SADI).
The expectation for the Japanese serum is growing while the infections grow and specialists warn that they must be intensify actions of prevention and of eradication of mosquitoes.
